Endothelin inhibition: Novel therapy for prostate cancer

Journal of Urology

Volumn 170, Issue 6 II, 2003, Pages

  Nelson, Joel B ^a,b   Sellers, William R ^b   Smith, Matthew R ^b   Kantoff, Philip W ^b   Roach III, Mack ^b   Oh, William K ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Clinical trial; Endothelin receptors; Endothelin 1; Metastases; Prostatic neoplasms

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ATRASENTAN; COLLAGEN; DEOXYPYRIDINOLINE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ASTHENIA; BONE METABOLISM; CANCER GROWTH; CANCER PAIN; CLINICAL TRIAL; CONFERENCE PAPER; HEADACHE; HUMAN; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RHINITIS;

EID: 0242440323     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000096372.07687.86     Document Type: Conference Paper

References (20)

1. Huggins, C.: Endocrine-induced regression of cancers. In: Nobel Lectures. Amsterdam: Elsevier Publishing Co., pp. 235-247, 1970
2. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W. S., Kim, W. Y. and Simons, J. W.: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542, 1995
3. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsu, Y. et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332: 411, 1988
4. Casey, M. L., Byrd, W. and MacDonald, P. C.: Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metabol, 74: 223, 1992
5. Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A. et al: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med, 1: 944, 1995
6. Nelson, J. B., Chan-Tack, K., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S. et al: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res, 56: 663, 1996
7. Papandreou, C. N., Usmani, B., Geng, Y., Bogenrieder, T., Freeman, R., Wilk, S. et al: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med, 4: 50, 1998
8. Kobayashi, S., Tang, R., Wang, B., Opgenorth, T., Langenstroer, P., Shapiro, I. et al: Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol Pharmacol, 45: 306, 1994
9. Wagner, O. F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P. J. et al: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem, 267: 16066, 1992
10. Gohji, K., Kitazawa, S., Tamada, H., Katsuoka, Y. and Nakajima, M.: Expression of endothelin receptor A associated with prostate cancer progression. J Urol, 165: 1033, 2001
11. Nelson, J. B., Lee, W.-H., Nguyen, S. H., Jarrard, D. F., Brooks, J. D., Magnuson, S. R. et al: Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res, 57: 35, 1997
12. Bird, A. P.: CpG-rich islands and the function of DNA methylation. Nature, 321: 209, 1986
13. Udan, M. S., Pflug, B. R. and Nelson, J. B.: Endothelin-1 promotes survival of prostate cancer cells through activation of Akt. J Urol, suppl., 163: 31, abstract 134, 2000
14. Alam, A. S., Gallagher, A., Shankar, V., Ghatei, M. A., Datta, H. K., Huang, C. L. et al: Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology, 130: 3617, 1992
15. Nelson, J. B., Nguyen, S. H., Wu-Wong, J. R., Opgenorth, T. J., Dixon, D. B., Chung, L. W. et al: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology, 53: 1063, 1999
16. Opgenorth, T. J., Adler, A. L., Calzadilla, S. V., Chiou, W. J., Dayton, B. D., Dixon, D. B. et al: Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther, 276: 473, 1996
17. Carducci, M. A., Nelson, J. B., Bowling, M. K., Rogers, T., Eisenberger, M. A., Sinibaldi, V. et al: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol, 20: 2171, 2002
18. Nelson, J. B., Carducci, M. A., Dawson, M., Hippensteel, R. L., Padley, R. J. and Janus, T. J.: Preliminary phase II results using ABT-627, an endothelin-A selective receptor antagonist, in men with symptomatic hormone refractory prostate cancer. J Urol, suppl., 163: 159, abstract 709, 2000
19. Carducci, M. A., Nelson, J. B., Padley, R. J., Janus, T. and Hippensteel, R.: The endothelin-A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: a multinational, randomized, double-blind, placebo-controlled trial. Proc Am Soc Clin Oncol, 20: 174a, abstract 694, 2001
20. Nelson, J. B., Carducci, M. A., Padley, R. J., Janus, T., Humerickhouse, R. and Hippensteel, R.: The endothelin-A receptor antagonist atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer. Proc Am Soc Clin Oncol, 20: 4a, abstract 12, 2001